|
Can’t access the links? Add “links.gd” to the allowlist of your content blocking software. |
|
|
The US Department of Justice issued a letter to all State Medicaid Administrators January 24 encouraging the administrators to ensure patients with both Hepatitis C (HCV) and substance use disorder (SUD) have access to direct-acting antivirals.
Washington State Apple Health (Medicaid) already has policies in place to treat patients with both HCV and SUD. The direct-acting antiviral drug MavyretTM to treat HCV is preferred and sobriety is not required. Anyone licensed to prescribe is allowed to screen and treat Apple Health members for HCV.
To eliminate HCV in Washington, the Health Care Authority encourages all providers to do the following:
- Test all adults 18 years and older at least once.
- Test all pregnant women during each pregnancy.
- Regularly screen patients with risk factors, including people who inject drugs.
- Reach out to patients who have tested positive but have no history of treatment.
Apple Health coverage and policy
Drug (treatment)
|
Policy
|
| Mavyret (HCV) |
- Preferred
- No prior authorization
- No sobriety requirement
- No liver biopsy or imaging required
|
| Buprenorphine - SUD |
- Preferred
- No prior authorization
|
| Naltrexone - SUD |
- Preferred
- No prior authorization
|
| Naloxone - SUD |
- Preferred
- No prior authorization
|
|
|
|
|